Results 41 to 50 of about 1,564,685 (307)

Protective efficacy against influenza A H3N2 virus of M2 VLP immune sera.

open access: yes, 2013
Immune sera collected from M2 VLP vaccinated mice at 4 weeks after boost vaccination were incubated with a lethal dose of A/Philippines/82 (H3N2) influenza virus at room temperature for 30 min.
Kyoung-Mi Park (329009)   +9 more
core   +1 more source

Biological and protective properties of immune sera directed to the influenza virus neuraminidase [PDF]

open access: yes, 2015
The envelope of influenza A viruses contains two large antigens, hemagglutinin (HA) and neuraminidase (NA). Conventional influenza virus vaccines induce neutralizing antibodies that are predominantly directed to the HA globular head, a domain that is ...
Stefan J. Halbherr   +13 more
core   +1 more source

The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom

open access: yesFrontiers in Immunology, 2021
To determine whether the neutralization activity of monoclonal antibodies, convalescent sera and vaccine-elicited sera was affected by the top five epidemic SARS-CoV-2 variants in the UK, including D614G+L18F+A222V, D614G+A222V, D614G+S477N, VOC-202012 ...
Jiajing Wu   +19 more
doaj   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad   +9 more
wiley   +1 more source

Analysis of B. burgdorferi-specific immune sera by immunoblotting.

open access: yes, 2013
The whole-cell lysates of B. burgdorferi WT, sVlsE, and ΔVlsE clones (106 cells/lane) were treated with anti-WT, anti-sVlsE, or anti-ΔVlsE (panel A, B, and C, respectively) immune sera collected from C3H mice at day 28 post infection.
Troy Bankhead (70620)   +1 more
core   +1 more source

«FREE» AND «BOUND» ANTIBODIES AGAINST HIV–1 STRUCTURE PROTEINS AT EARLY STAGE OF THE DISEASE

open access: yesМедицинская иммунология, 2014
. Using ELISA and immunoblotting we have monitored the activity of “free” antibodies against virus structure proteins in the sera of HIV–infected patients at the stage of the developing humoral immune response. Further, a comparative assessment of “free”
G. A. Rjazanova   +2 more
doaj   +1 more source

Serological diagnosis of toxoplasmosis: evaluation of the commercial test recomLine Toxoplasma IgG immunoblot (Mikrogen) based on recombinant antigens

open access: yesParasite, 2022
Background: IgG detection to determine immune status to Toxoplasma gondii infection and seroconversion mainly relies on ELISA techniques and, if necessary, on a confirmatory test, Western blot.
Jean-Pierre Vincent   +6 more
doaj   +1 more source

“We Cannot Talk as a Family”: Complexities of Survivorship Communication Among Hispanic/Latino Young Adult Survivors of Childhood Cancer, Parents, and Clinicians

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Young adult childhood cancer survivors (YA‐CCS) have an increased risk of treatment‐related health complications throughout their lives. Lifelong survivorship care is recommended, yet many YA‐CCS experience disruptions in care during pediatric‐to‐adult transitions and do not receive recommended survivorship care.
Kevin Shanchen Pu   +8 more
wiley   +1 more source

Neutralization of the boost vaccines by mice immune sera after the prime vaccination.

open access: yes, 2021
Mouse immune sera against VSV-SARS-CoV-2 msp-SF-Gtc were prepared by vaccinating interferon α and β receptor knock out mice (Ifnar-/- mice, Jackson Laboratory, B6.129S2-Ifnar1tm1Agt/Mmjax) once with 5X108 PFU of rVSVInd-msp-SF-Gtc.
Taewoo Kim (1456888)   +30 more
core   +1 more source

Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis

open access: yesFrontiers in Immunology, 2018
A Phase 1b/2a clinical trial of NDV-3A vaccine containing a Candida albicans recombinant Als3 protein formulated with alum protected women <40 years old from recurrent vulvovaginal candidiasis (RVVC).
Priya Uppuluri   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy